Scarica l'app Stockscreener
1.80
11.11%
0.18
Precedente Chiudi:
$1.62
Aprire:
$1.63
Volume 24 ore:
4.71M
Relative Volume:
1.15
Capitalizzazione di mercato:
$404.51M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.8491
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
+6.51%
1M Prestazione:
+9.76%
6M Prestazione:
+73.08%
1 anno Prestazione:
+27.66%
Intervallo 1D:
$1.63
$1.8265
Intervallo di 1 settimana:
$1.56
$1.84
Portata 52W:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.80 | 364.06M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Allogene Therapeutics (NASDAQ:ALLO) Cut to "Sell" at Wall Street Zen - MarketBeat
Will Allogene Therapeutics Inc. benefit from geopolitical trendsBreakout Watch & Daily Profit Maximizing Tips - mfd.ru
Aug Selloffs: Is Bank of Montreal on track to beat earningsPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Bond Watch: Will Allogene Therapeutics Inc stock hit new highs in YEARWeekly Trend Report & Technical Pattern Based Signals - baoquankhu1.vn
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance
Why Allogene Therapeutics Inc. stock could see breakout soonTreasury Yields & Stock Portfolio Risk Management - mfd.ru
Follicular Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic - Barchart.com
Aug Drivers: Will Allogene Therapeutics Inc stock hit new highs in YEAREarnings Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Allogene Therapeutics Approaches a Defining Period for Its Platform - AD HOC NEWS
Don't Ignore The Insider Selling In Allogene Therapeutics - 富途牛牛
Allogene Therapeutics explores cell therapy trial at ASTCT meeting - Traders Union
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Yahoo Finance
Allogene EVP Roberts sells $63,189 in stock, gains options By Investing.com - Investing.com Canada
Allogene Therapeutics CEO Chang David D sells $171k in stock - Investing.com Canada
Allogene Therapeutics SVP sells $13k in stock By Investing.com - Investing.com Australia
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN
Allogene Therapeutics (NASDAQ:ALLO) EVP Sells $63,189.00 in Stock - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) CEO David Chang Sells 95,269 Shares - MarketBeat
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,549 Shares of Stock - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) CFO Sells $42,241.76 in Stock - MarketBeat
Allogene Therapeutics (ALLO) Is Up 24.1% After Extended Cash Runway and CAR T Trial Progress - Yahoo Finance
Allogene Therapeutics SVP sells $13k in stock - Investing.com
Allogene Therapeutics SVP sells $40k in stock By Investing.com - Investing.com Canada
Allogene Therapeutics SVP sells $40k in stock - Investing.com
Allogene Therapeutics (NASDAQ:ALLO) SVP Earl Martin Douglas Sells 22,900 Shares - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene Therapeutics Gains Following Positive Ratings and Strategic Plans - StocksToTrade
Allogene Therapeutics’ Strategic Upgrades Signal Strong Market Potential - timothysykes.com
Allogene Therapeutics Sees Potential as Citizens Upgrades to Outperform - StocksToTrade
Setup Watch: Is Allogene Therapeutics Inc attractive at current valuation2025 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
Allogene Therapeutics Gears Up for 2026 as Biotech Positivity Fuels Growth Prospects - StocksToTrade
Record $2.5B Sector Start Spotlights Clinical Oncology Plays - Baystreet.ca
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) EVP Sells 26,269 Shares of Stock - MarketBeat
Take Profit: What are the future prospects of Allogene Therapeutics IncBear Alert & Weekly Momentum Stock Picks - baoquankhu1.vn
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - ADVFN
Insider Trends: What are the future prospects of Allogene Therapeutics IncTrade Risk Report & Fast Moving Stock Watchlists - baoquankhu1.vn
Decliners Report: Is AMZE part of any ETF2025 Winners & Losers & Safe Entry Zone Tips - baoquankhu1.vn
Earnings Miss: Is Allogene Therapeutics Inc stock a top momentum play - Bộ Nội Vụ
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sell Signal: What are the risks of holding Allogene Therapeutics Inc2025 Technical Overview & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Earnings Risk: Will Allogene Therapeutics Inc stock hit new highs in YEARJobs Report & Weekly Market Pulse Alerts - baoquankhu1.vn
Allogene Therapeutics Sees Bright Prospects with Upgrades and Awards - StocksToTrade
Allogene Therapeutics Sees Optimistic Outlook as Market Interest Grows - timothysykes.com
Allogene Therapeutics Stock Surges After Promising Market Developments - timothysykes.com
Allogene Therapeutics’ Stock Surges as Analysts Optimistic on Future Outlook - StocksToTrade
Allogene Therapeutics Stock Rises Amid Key Developments - StocksToTrade
Allogene Therapeutics Stock Upgraded as ALPHA3 Trial Inspires Market Confidence - timothysykes.com
Allogene Therapeutics Surges on Positive Analyst Ratings and Arbitration Wins - timothysykes.com
Allogene Therapeutics (ALLO) Upgraded by Citizens to Market Outp - GuruFocus
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):